Nervous System Neoplasms with MCC DRG

DRG 054 encompasses inpatient admissions for nervous system neoplasms with a Major Complication or Comorbidity, reflecting high clinical complexity. This Diagnosis-Related Group matters for inpatient reimbursement because its higher resource intensity and payment weight affect Medicare payment to hospitals.

DRG 054 Overview

DRG 054 covers inpatient admissions for nervous system neoplasms with a Major Complication or Comorbidity present, typically including malignant and selected benign brain and spinal tumors with significant comorbid conditions. This Diagnosis-Related Group groups cases with higher clinical complexity and resource use, which affects Medicare payment weight and hospital reimbursement. Cases in this category often involve neurosurgical procedures, intensive monitoring, and extended inpatient care. Accurate coding of diagnoses and complications is critical to assign the appropriate Diagnosis-Related Group for Medicare payment purposes.

Trials of perioperative and intraoperative interventions to reduce neurological morbidity and improve resection outcomes: randomized or controlled studies evaluating strategies such as advanced neuro-monitoring protocols, optimized anesthesia techniques, intraoperative imaging adjuncts, or enhanced surgical workflows in patients undergoing craniotomy or spinal surgery for malignant or benign nervous system tumors with major complications/comorbidities. These studies enroll high-acuity inpatients (often elderly or medically complex) who are at increased risk for neurologic decline, infection, or bleeding, and they measure short-term functional status, complication rates, and length of stay — outcomes that directly affect hospital resource use and reimbursement under this DRG. For providers and payers, evidence that specific perioperative practices reduce complications or shorten ICU/hospital days supports care pathways that can improve quality metrics and control costs for this high-cost patient group.
Comparative effectiveness studies of adjunctive medical or supportive therapies during acute inpatient management: observational cohort studies or pragmatic randomized trials comparing approaches such as different corticosteroid regimens, seizure prophylaxis strategies, anticoagulation management, or infection prevention bundles in patients hospitalized with nervous system neoplasms complicated by edema, seizures, thromboembolism, or infection. These trials focus on medically complex inpatients, including those with comorbid organ dysfunction or immunosuppression, to determine which inpatient medical management strategies reduce major complications, readmissions, and in-hospital mortality. Results inform clinical guidelines and payer decisions about acceptable practice patterns and may identify cost-saving care protocols without compromising outcomes in this DRG population.
Post-discharge outcomes and rehabilitation effectiveness research: longitudinal studies and randomized or pragmatic trials assessing inpatient-to-outpatient transitions, timing and intensity of inpatient rehabilitation, or early supportive care interventions for patients discharged after treatment for nervous system neoplasms with major complications. These studies evaluate functional recovery, readmission risk, use of home health or skilled nursing, and long-term neurologic outcomes among survivors who often have new or worsened disability, and they identify predictors of resource use and post-acute care needs. Payers and hospitals use this evidence to design discharge planning, bundle payments, and care coordination programs that reduce costly readmissions and align reimbursement with improved functional outcomes for this DRG.

Trials of perioperative and intraoperative interventions to reduce neurological morbidity and improve resection outcomes: randomized or controlled studies evaluating strategies such as advanced neuro-monitoring protocols, optimized anesthesia techniques, intraoperative imaging adjuncts, or enhanced surgical workflows in patients undergoing craniotomy or spinal surgery for malignant or benign nervous system tumors with major complications/comorbidities. These studies enroll high-acuity inpatients (often elderly or medically complex) who are at increased risk for neurologic decline, infection, or bleeding, and they measure short-term functional status, complication rates, and length of stay — outcomes that directly affect hospital resource use and reimbursement under this DRG. For providers and payers, evidence that specific perioperative practices reduce complications or shorten ICU/hospital days supports care pathways that can improve quality metrics and control costs for this high-cost patient group.
Comparative effectiveness studies of adjunctive medical or supportive therapies during acute inpatient management: observational cohort studies or pragmatic randomized trials comparing approaches such as different corticosteroid regimens, seizure prophylaxis strategies, anticoagulation management, or infection prevention bundles in patients hospitalized with nervous system neoplasms complicated by edema, seizures, thromboembolism, or infection. These trials focus on medically complex inpatients, including those with comorbid organ dysfunction or immunosuppression, to determine which inpatient medical management strategies reduce major complications, readmissions, and in-hospital mortality. Results inform clinical guidelines and payer decisions about acceptable practice patterns and may identify cost-saving care protocols without compromising outcomes in this DRG population.
Post-discharge outcomes and rehabilitation effectiveness research: longitudinal studies and randomized or pragmatic trials assessing inpatient-to-outpatient transitions, timing and intensity of inpatient rehabilitation, or early supportive care interventions for patients discharged after treatment for nervous system neoplasms with major complications. These studies evaluate functional recovery, readmission risk, use of home health or skilled nursing, and long-term neurologic outcomes among survivors who often have new or worsened disability, and they identify predictors of resource use and post-acute care needs. Payers and hospitals use this evidence to design discharge planning, bundle payments, and care coordination programs that reduce costly readmissions and align reimbursement with improved functional outcomes for this DRG.

OpenPayer

Summary & Overview

Nervous System Neoplasms with MCC: Inpatient Reimbursement Overview

DRG 054 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes